Table 2. Summary of the results of the effect sizes of MSC treatment on pain relief.

First author/year	MSC	Source	Conventional meta-analysis						Network meta-analysis				Conventional meta-analysis				Network meta-analysis
			WMD (95% CI)	Weight (%)	Subgroup analysis				WMD (95% CI)	P value	SUCRA [0-100]		Subgroup analysis				WMD (95% CI)	P value	SUCRA [0-100]
					WMD (95% CI)	P value	Weight (%)						WMD (95% CI)	P value	Weight (%)
Vega/2015	BM-MSCs	Allogenic	−8.00 (−27.60, 11.60)	11.02	−15.17 (−26.05, −4.29)	0.006	35.77		−15.17 (−26.05, −4.29)	0.006	48.4		−10.84 (−25.06, 3.38)	0.135	20.92		−10.88 (−27.01, 5.26)	0.187	33.7
Gupta/2016			−14.00 (−34.67, 6.67)	9.90
Lamo-Espinosa/2016, 2018		Autologous	−33.15 (−55.39, −10.92)	8.56									−21.26 (−38.14, −4.39)	0.014	14.85		−20.91 (−39.78, −2.04)	0.030	62.4
Emadedin/2018			−5.10 (−31.03, 20.83)	6.30
Kuah/2018	AD-MSCs	Allogenic	−21.12 (−37.49, −4.75)	15.80	−26.05 (−36.06, −16.04)	<0.001	42.20		−26.05 (−36.06, −16.04)	<0.001	92.0		−21.12 (−37.49, −4.75)	0.014	15.80		−21.12 (−40.70, −1.54)	0.035	63.0
Lee/2019		Autologous	−29.0 (−41.66, −16.34)	26.40									-29.0 (−41.66, −16.34)	0.011	26.40		−29.0 (−45.61, −12.39)	0.001	84.8
Matas/2019	UC-MSCs	Allogenic	−17.65 (−31.51, −3.79)	22.03	−17.65 (−31.51, −3.79)	0.013	22.03		−17.65 (−31.51, −3.79)	0.013	59.4		−17.65 (−31.51, −3.79)	0.013	22.03		−17.65 (−31.19, −0.11)	0.049	53.1